pocketful logo
Ind-Swift Laboratories Ltd logo

Ind-Swift Laboratories Ltd

NSE: INDSWFTLAB BSE: 532305

₹137.54

(1.07%)

Fri, 08 May 2026, 09:08 am

mtf coin illustrationMTF 5x

Ind-Swift Laboratories Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    1215.28

  • Net Profit

    250.53

  • P/B

    0.53

  • Sector P/E

    34.49

  • P/E

    2.30

  • EV/EBITDA

    0.62

  • Debt/Equity (Industry)

    0.24

  • Interest Cover (Industry)

    9.69

  • ROCE (Industry)

    13.46

  • RONW (Industry)

    12.65

  • ROE

    0.14

  • ROCE

    0.63

  • Debt/Equity

    0.11

  • EPS (TTM)

    5.45

  • Dividend Yield

    0

  • Book Value

    157.69

  • Interest Cover

    3.01

Analysis

all

thumbs up icon

Pros

  • Ind-Swift Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Whilst loss making Ind-Swift Laboratories has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 1.4% per year.
  • Whilst loss making Ind-Swift Laboratories has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • The level of debt compared to net worth has been reduced over the past 5 years (223.2% vs 188.2% today).
  • The tenure for the Ind-Swift Laboratories board of directors is about average.
thumbs up icon

Cons

  • Unable to calculate sustainability of dividends as Ind-Swift Laboratories has not reported any payouts.
  • Unable to evaluate Ind-Swift Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Ind-Swift Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Debt is not well covered by operating cash flow (13.1%, less than 20% of total debt).
  • Debt is not covered by short term assets, assets are 0.8x debt.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters42.9939.5039.5040.9440.94
FII13.8814.3314.804.273.07
DII0.000.680.680.910.91
Public43.1245.5045.0253.8755.07
Government00000

Read More

Technical Analysis

RSI

49.39

MACD

0.25

50 DMA

140.24

200 DMA

112.73

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic199.55170.05153.79140.55124.29111.0581.55
Fibonacci170.05158.78151.82140.55129.28122.32111.05
Camarilla145.65142.95140.24140.55134.84132.13129.43

Pivots Level: Classic

R3

+59.00

199.55

R2

+29.50

170.05

R1

+13.25

153.79

140.55
140.55
Pivot Point
LTP: 138.67

S1

-16.25

124.29

S2

-29.50

111.05

S3

-59.00

81.55

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    139.60

  • 20-EMA

    139.51

  • 30-EMA

    139.05

  • 50-EMA

    136.41

  • 100-EMA

    128.11

  • 200-EMA

    118.41

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
31 Jan 2026board-meetingsQuarterly Results, Nine Months Results
14 Nov 2025board-meetingsQuarterly Results
25 Aug 2025agm
20 Jan 2025egm
02 Sept 2024agm
24 Aug 2024agmAnnual General Meeting25 Sept 2024
28 Jun 2024egm
06 Sept 2023egm
31 Aug 2023agm
22 Aug 2023agmAnnual General Meeting25 Sept 2023

Read More

Peer Comparison

Ind-Swift Laboratories Ltd logo

Ind-Swift Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Cipla Ltd logo

Cipla Ltd

Lupin Ltd logo

Lupin Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Read More

Ind-Swift Laboratories Ltd About

Ind-Swift Laboratories as an API manufacturer the Company has shifted its focus to formulation as its key business driver.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1995

Headquarters

CEO

N R Munjal

Employees

Contact

Website icon

Website

http://www.indswiftlabs.com

Email icon

Email

investor@indswiftlabs.com, info@indswiftlabs.com

Phone icon

Phone

91-0172-5061850/2730920

Location icon

Location

SCO 850 Shivalik Enclave, NAC Manimajra, Chandigarh, Chandigarh, 160101

Read More

Ind-Swift Laboratories Ltd Company History

YearHistory
2013
  • R K Ummat was appointed as an Independent Director on the Board of the Company.
2014
  • Dr. Vinay Kumar Arora was appointed as an Independent Director.
2018
  • The company acquired KEC Bikaner Sikar Transmission Private Limited.
2020
  • Ind-Swift Labs tied up with a reputed generic player in the USA to launch generic Fexofenadine.
2021
  • Ind-Swift Laboratories Limited received the North India Best Employer Award.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
HCP INVESTMENTSSell700000131.1420 Apr 2026
D3 STOCK VISION LLPSell484361132.8117 Apr 2026
SAHASTRAA ADVISORS PRIVATE LIMITEDBuy475000131.7417 Apr 2026
F3 ADVISORS PRIVATE LIMITEDBuy702431133.2517 Apr 2026
NOVA GLOBAL OPPORTUNITIES FUND PCC - TOUCHSTONEBuy803387138.0717 Apr 2026
SHARE INDIA SECURITIES LIMITEDBuy689971134.2817 Apr 2026
PARTH INFIN BROKERS PVT LTDBuy478673132.7617 Apr 2026
MANSI SHARE AND STOCK BROKING PRIVATE LIMITEDBuy798784132.6617 Apr 2026
D3 STOCK VISION LLPBuy479361132.3817 Apr 2026
MANSI SHARE AND STOCK BROKING PRIVATE LIMITEDSell696283136.1717 Apr 2026

Read More

Ind-Swift Laboratories Ltd News

Ind-Swift Labs Passes 4 Special Resolutions via Postal Ballot

Ind-Swift Laboratories passes 4 special resolutions via postal ballot on April 30, 2026, including MD appointments and remuneration approval, with over 99.87% votes in favour.

05 May 2026

companies

HCP Investments Sells 7.5% Stake in Ind-Swift Labs

HCP Investments disposed of 6,503,423 equity shares representing 7.5% stake in Ind-Swift Laboratories through open market transactions between April 13-17, 2026, reducing its holding to 1.149%.

23 Apr 2026

companies

HCP Investments Sells 7.5% Stake in Ind-Swift Labs

HCP Investments disposed of 6,503,423 equity shares representing 7.5% stake in Ind-Swift Laboratories through open market transactions between April 13-17, 2026, reducing its holding to 1.149%.

22 Apr 2026

companies

Ind-Swift Labs Clarifies Trading Volume Surge

Ind-Swift Laboratories responds to BSE inquiry about trading volume spike, attributing it to recent arbitration award disclosure with no other material developments.

10 Apr 2026

companies

Ind Swift Labs Wins Arbitration Against PI Industries

Arbitral Tribunal rejects all claims by PI Industries Limited and counterclaims by Ind-Swift Laboratories, concluding proceedings with zero financial impact on the company.

08 Apr 2026

companies

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800